Molecular profiles of high‐grade and low‐grade pseudomyxoma peritonei

التفاصيل البيبلوغرافية
العنوان: Molecular profiles of high‐grade and low‐grade pseudomyxoma peritonei
المؤلفون: Hideaki Yano, Yoichi Furukawa, Yumi Terakado, Ryuichiro Suda, Tsuneo Ikenoue, Naohide Yamashita, Yoshimasa Gohda, Toru Igari, Kiyoshi Yamaguchi, Rei Noguchi, Yasunori Ohta
المصدر: Cancer Medicine
بيانات النشر: Wiley, 2015.
سنة النشر: 2015
مصطلحات موضوعية: Male, Cancer Research, Pathology, medicine.medical_specialty, DNA Mutational Analysis, medicine.disease_cause, Pathogenesis, PMCA, medicine, GNAS complex locus, Humans, Pseudomyxoma peritonei, Radiology, Nuclear Medicine and imaging, TP53, Gene, Peritoneal Neoplasms, Original Research, Aged, Aged, 80 and over, Mutation, pseudomyxoma peritonei, biology, business.industry, Gene Expression Profiling, Clinical Cancer Research, Cancer, Middle Aged, medicine.disease, Combined Modality Therapy, Immunohistochemistry, Phenotype, DPAM, Oncology, biology.protein, Female, KRAS, Neoplasm Grading, Tumor Suppressor Protein p53, Transcriptome, business, Biomarkers
الوصف: Pseudomyxoma peritonei (PMP) is a rare disease exhibiting a distinct clinical feature caused by cancerous cells that produce mucinous fluid in the abdominal cavity. PMPs originate most frequently from the appendix and less frequently from the ovary. This disease can range from benign to malignant, and histologically, PMP is classified into two types: disseminated peritoneal adenomucinosis (DPAM) representing the milder phenotype, and peritoneal mucinous adenocarcinomas (PMCA) representing the aggressive phenotype. Although histological classification is clinically useful, the pathogenesis of PMP remains largely unknown. To elucidate the molecular mechanisms underlying PMP, we analyzed 18 PMP tumors comprising 10 DPAMs and 8 PMCAs. DNA was extracted from tumor and matched non‐tumorous tissues, and was sequenced using Ion AmpliSeq Cancer Panel containing 50 cancer‐related genes. Analysis of the data identified a total of 35 somatic mutations in 10 genes, and all mutations were judged as pathological mutations. Mutations were frequently identified in KRAS (14/18) and GNAS (8/18). Interestingly, TP53 mutations were found in three of the eight PMCAs, but not in the DPAMs. PIK3CA and AKT1 mutations were also identified in two PMCAs, but not in the DPAMs. These results suggested that KRAS and/or GNAS mutations are common genetic features of PMP, and that mutations in TP53 and/or genes related to the PI3K‐AKT pathway may render malignant properties to PMP. These findings may be useful for the understanding of tumor characteristics, and facilitate the development of therapeutic strategies.
تدمد: 2045-7634
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86937af14713bdf71cbcfff5926e066b
https://doi.org/10.1002/cam4.542
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....86937af14713bdf71cbcfff5926e066b
قاعدة البيانات: OpenAIRE